Generate co-founder Molly Gibson and CEO Mike Nally
November 18, 2021 05:00 AM EST
Financing

Flag­ship's ma­chine learn­ing start­up Gen­er­ate bags $370M in lat­est round with plans for a big hir­ing spree

Kyle Blankenship

As the fu­ture of ma­chine learn­ing and AI promis­es to make ma­jor break­throughs in drug de­vel­op­ment, a suite of star­tups is look­ing to scale their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times